Morgan Stanley raised the firm’s price target on Johnson & Johnson to $178 from $176 and keeps an Equal Weight rating on the shares. Ahead of Q3 earnings, the firm adjusted models for IQVIA trends as well as intra-quarter updates, the analyst tells investors in a preview for the biopharma group.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on JNJ:
- GoodRx, others in talks with White House to join TrumpRx, Reuters reports
- Trump Trade: Generics to be excluded from pharma tariff plan
- Generics to be excluded from Trump’s pharma tariff plan, WSJ reports
- Balanced Outlook for Johnson & Johnson: Hold Rating Amid Stable Revenue and Slight EPS Decline
- Protagonist Therapeutics price target raised to $74 from $62 at Clear Street